What is Galectin Therapeutics Inc (GALT) stock price today?

Galectin Therapeutics Inc (GALT) currently trades at $2.27 per share. The stock has a market capitalization of $156.01M and a P/E ratio of —x.

Is GALT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Galectin Therapeutics Inc has a Smart Value Score of 17/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -37.81.

Is Galectin Therapeutics Inc financially healthy?

Galectin Therapeutics Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -37.81 places it in the distress.

GALT

Galectin Therapeutics Inc

NASDAQ: GALT · HEALTHCARE · BIOTECHNOLOGY

$2.27

+0.89% today

Updated 2026-04-30

Market cap

$156.01M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.48

Dividend yield

—

52W range

$1 – $7

Volume

0.3M

Market cap

$156.01M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.48

Dividend yield

—

52W range

$1 – $7

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-37.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$11.00

+384.58%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity -0.98x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -37.81 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-6.04M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-38.78M	$-41.07M	$-47.05M	$-30.84M	$-5.50M
EPS	—	—	—	—	$-0.48
Free cash flow	$-31.06M	$-32.97M	$-41.77M	$-23.88M	$-6.04M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
GALT	$156.01M	17	4.3	3.0	5.0	4.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Galectin Therapeutics Inc trades at $2.27. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -37.81, it sits in the distress.

Frequently asked questions

What is Galectin Therapeutics Inc's stock price?

Galectin Therapeutics Inc (GALT) trades at $2.27.

Is Galectin Therapeutics Inc overvalued?

Smart Value Score 17/100 (Grade F, Strong Sell).

What is the price target of Galectin Therapeutics Inc (GALT)?

The analyst target price is $11.00, representing +384.6% upside from the current price of $2.27.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-37.81 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

galectintherapeutics.com

Quick metrics

P/S ratio—

ROE-3,728.00%

Beta1.04

50D MA$2.77

200D MA$3.96

Shares out0.07B

Float0.05B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

GALT vs LLY →GALT vs JNJ →GALT vs ABBV →Stock screener →